INTERNAL TRANSMITTAL — NOT PART OF THE PROVIDER-FACING DOCUMENT

Cover Memo — Collaborative Review

PRECISO™ Provider Overview — Pediatric & Academic Medical Center Segment

To Executive Office; Clinical & Scientific Affairs; Legal & Compliance; Brand/Marketing
From Tom Cobin, VP, Commercial Strategy
Date July 28, 2026
Status Draft v0.3 — Internal Collaborative Review — Not Approved for External Distribution

The attached two-page overview (following this memo) is formatted to appear exactly as it would if approved — no draft markings, internal notes, or placeholders appear in the provider-facing pages. It is written as a reusable, institution-agnostic asset for the pediatric and academic-medical-center segment: no customer is named anywhere in the body.

Content and emphasis were shaped by two current outreach conversations — Nicklaus Children's Hospital and St. Jude Children's Research Hospital — which is why the overview leans on NICU/PICU acuity, oncology-adjacent functional precision medicine, hereditary-risk/survivorship follow-up, and logistics infrastructure for extending testing across affiliate and satellite sites. That targeting context is for internal use only and should not be inferred by anyone reading the finished piece.

01

Required Confirmations Before External Release

  1. Insert finalized sender contact information (name, title, Renoviant email and phone) on page 1 before distribution.
  2. All clinical and cost-effectiveness citations (sources 1–6, page 2) require Clinical + Scientific + Legal review and sign-off per the Approval Matrix before external circulation — including source 6, the functional-precision-oncology reference, which does not name an institution in the body but is still an identifiable published study and requires the same claims review.
  3. This piece is intentionally institution-agnostic. If cover correspondence or an email names a specific recipient (e.g., “St. Jude”), confirm the exact legal entity first — our source materials point to St. Jude Children's Research Hospital (Memphis), not “St. Jude's Medical Center.”
  4. Confirm the journey diagram, icon treatment, and card layout on pages 1–2 comply with the approved visual system (Section 18–24 of the Brand Standards & Governance Manual) before this is treated as a template for other segments.
02

Review Process

Post this file to SharePoint or OneDrive with edit access for the reviewers above. Route for Brand, Executive, Clinical/Scientific, Legal, and Partner review as applicable, consistent with the Approval Matrix in the PRECISO Brand Standards & Governance Manual (v1.0, effective July 24, 2026). Once resolved and approved, remove this cover memo, finalize the filename, and export a controlled PDF for external delivery.

Renoviant, Inc. — Confidential Internal Working Document
PRECISO™ A Renoviant Company
Page 1 of 2
A Renoviant Company

PRECISO™

Precision Healthcare Infrastructure Powered by Genomics and Clinical Intelligence

PRECISO structures the journey from physician-directed whole genome sequencing through evidence-based reporting and longitudinal care. The result is a durable, unified genomic resource that evolves over time with emerging new scientific knowledge.

CARD-BASED CONVENIENCE SCALABLE BY DESIGN

The foundation of PRECISO is a patient sample collected using the proprietary PRECISO Blood Spot Card (BSC): a low-burden process designed for broad, rapid, and efficient deployment.

01

The PRECISO Journey

01

VeriCense™

Identity, consent, access-control, and data-governance infrastructure.

02

Sample Collection

PRECISO BSC
03

PRECISO Report™

Clinical intelligence: organizing genomic findings into actionable insights for providers, using approved regulatory guidelines and standards.

04

PRECISO Care™

Physician engagement, genetic consultation, and Nurse Navigator support for clinicians & staff.

02

Operating Model Comparison

Traditional Testing

  • One-time test, static report
  • Isolated sample collection
  • Limited post-report continuity
  • Fragmented consent processes

PRECISO Platform

  • Durable record, updated & revisited as evidence evolves
  • Blood sample collection unified within a broader workflow
  • PRECISO Care™ follow-up and longitudinal support
  • VeriCense™-enabled identity, consent, and governance
PRECISO.ai  |  A Renoviant Company v0.3  |  July 2026  |  Page 1 of 2
PRECISO™ A Renoviant Company
Page 2 of 2

Independent, peer-reviewed research provides the clinical rationale for whole-genome sequencing across populations and care settings.

early risk stratification

Whole Genome Sequencing can identify markers in patients who otherwise may be unaware of risk until disease onset and symptomatic presentation.

NICU / PICU
⅓ roughly one-third
of critically ill infants

Rapid genomic sequencing identifies an actionable diagnosis in roughly one-third of critically ill infants, often guiding changes in care within days.23

EFFICIENCY OF CARE

Genomic diagnosis is linked to fewer hospitalizations, fewer ER visits, and lower per-patient costs within two years, vs. prolonged conventional workups.1

PHARMACOGENOMICS

Genetic insights increasingly guide therapy selection, with published analyses reporting favorable cost-effectiveness vs. empiric treatment.4 Findings are relevant to survivorship and family cascade testing.5

Functional Precision MEDICINE: PEDIATRIC ONCOLOGY

Emerging research pairs live tumor drug-response testing with genomic findings to guide real-time treatment selection in pediatric oncology, with early results reporting meaningful clinical improvement in relapsed and refractory cases.6 PRECISO's infrastructure is designed to support this pathway, from initial genomic risk identification through clinician-guided longitudinal follow-up.

FirstSource — Deployment & Logistics Infrastructure

FirstSource, Renoviant's logistics and fulfillment infrastructure, coordinates specimen-kit distribution, chain-of-custody, and courier logistics for the PRECISO Blood Spot Card across a health system's main campus, satellite clinics, and affiliate sites — extending testing access without duplicating an institution's existing lab investment.

Compliance, Consent & Governance

Any collaboration operates within the institution's existing IRB, consent, and clinical-governance protocols. PRECISO integrates with VeriCense™ and is designed to support — not replace — genetic counseling, confirmatory testing, and clinical decision-making. Laboratory sequencing is performed by CLIA/CAP-certified partners; PRECISO coordinates the surrounding workflow.

03

Proposed Scope for an Initial Discussion

  1. 1 Identify an initial clinical use case aligned to institutional priorities
  2. 2 Review consent, IRB, and data-governance requirements with compliance and legal teams
  3. 3 Assess workflow integration with the existing genetics/genomics program and EHR
  4. 4 Scope the FirstSource logistics footprint across relevant sites
  5. 5 Establish a mutually agreed pilot timeline and success metrics

Notes

  1. GeneDx SAVES-Kids Study, ACMG Annual Meeting, 2026.
  2. Farnaes et al., NPJ Genomic Medicine, 2018.
  3. Providence Geno4ME / Rady Children's Hospital NICU outcomes, npj Genomic Medicine, 2025.
  4. WGS-TMB cost-effectiveness analysis, PharmacoEconomics, 2024.
  5. Providence Geno4ME WGS Population Program, npj Genomic Medicine, July 2025.
  6. Azzam et al., Nature Medicine, 2024.
© 2026 Renoviant, Inc. PRECISO, PRECISO Report, PRECISO Care, and VeriCense are trademarks of Renoviant, Inc. PRECISO.ai